β¨ Health Notices
21 FEBRUARY 2008 NEW ZEALAND GAZETTE, No. 31 715
Health
Medicines Act 1981
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Gutron
Active Ingredient: Midodrine hydrochloride 2.5mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Ltd
Manufacturer: Nycomed Austria GmbH, Linz, Austria
Note: This consent is valid for two years from 30 April 2008.
Product: Gutron
Active Ingredient: Midodrine hydrochloride 5mg
Dosage Form: Tablet
New Zealand Sponsor: Douglas Pharmaceuticals Ltd
Manufacturer: Nycomed Austria GmbH, Linz, Austria
Note: This consent is valid for two years from 30 April 2008.
Dated this 15th day of February 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go1206
Consent to the Distribution of a New Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Cetirizine
Active Ingredient: Cetirizine hydrochloride 10mg
Dosage Form: Film coated tablet
New Zealand Sponsor: REX Medical Ltd
Manufacturer: Cipla Ltd, Manufacturing Division, District Raigad, (Maharashtra), India
Dated this 15th day of February 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go1208
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Ziagen
Active Ingredient: Abacavir sulfate 351mg equivalent to 300mg abacavir
Dosage Form: Film coated tablet
New Zealand Sponsor: GlaxoSmithKline (NZ) Ltd
Manufacturer: Glaxo Operations UK Limited (t/a Glaxo Wellcome Operations), Ware, Hertfordshire, United Kingdom
Dated this 15th day of February 2008.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go1207
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2008, No 31
Gazette.govt.nz —
NZ Gazette 2008, No 31
β¨ LLM interpretation of page content
π₯ Renewal of Provisional Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare15 February 2008
Medicines, Provisional Consent, Gutron, Midodrine hydrochloride, Douglas Pharmaceuticals Ltd
- ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Consent to the Distribution of a New Medicine
π₯ Health & Social Welfare15 February 2008
Medicines, Consent, Cetirizine, REX Medical Ltd
- ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Consent to the Distribution of a Changed Medicine
π₯ Health & Social Welfare15 February 2008
Medicines, Consent, Ziagen, Abacavir sulfate, GlaxoSmithKline (NZ) Ltd
- ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate